Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
This grant funds early-stage clinical drug development for novel therapeutic agents targeting Alzheimer's Disease and related dementias.
About this program
The Seamless Early-Stage Clinical Drug Development grant supports innovative research aimed at developing new therapeutic agents for Alzheimer's Disease (AD) and Alzheimer's Disease-related dementias (ADRD). This funding opportunity is designed for researchers and organizations engaged in clinical trials that aim to transition from Phase 1 to Phase 2a, facilitating the development of effective treatments for these conditions. The grant encourages collaboration among academic institutions, industry partners, and healthcare organizations to accelerate the drug development process. Eligible applicants include academic institutions, nonprofit organizations, and small businesses that are focused on advancing therapeutic solutions for Alzheimer's Disease. The grant aims to foster a seamless transition between early-phase clinical trials, ensuring that promising therapeutic agents can move swiftly through the development pipeline. By providing financial support, this grant seeks to enhance the quality of research and ultimately improve patient outcomes in the field of neurodegenerative diseases.
Eligibility
Academic institutions, nonprofit organizations, and small businesses focused on Alzheimer's Disease research.
Requirements
- Clinical trial required
- Focus on Alzheimer's Disease and related dementias